id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-1994-0006,FDA,FDA-2020-E-1994,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-07-13T04:00:00Z,2023,7,2023-07-13T04:00:00Z,,2023-07-13T16:41:09Z,,0,0,0900006485ca10e5
FDA-2020-E-1994-0005,FDA,FDA-2020-E-1994,Determination of Regulatory Review Period for Purposes of Patent Extension; NOURIANZ,Notice,Determinations,2022-11-07T05:00:00Z,2022,11,2022-11-07T05:00:00Z,2023-01-07T04:59:59Z,2022-11-07T18:20:20Z,2022-24217,0,0,0900006485489888
FDA-2020-E-1994-0004,FDA,FDA-2020-E-1994,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-22T04:00:00Z,2022,9,2022-09-22T04:00:00Z,,2022-09-22T17:39:43Z,,0,0,090000648535110c
FDA-2020-E-1994-0003,FDA,FDA-2020-E-1994,Letter from U S Patent and Trademark Office,Other,Letter(s),2021-02-23T05:00:00Z,2021,2,2021-02-23T05:00:00Z,,2021-02-23T17:03:20Z,,0,0,0900006484a497d0
FDA-2020-E-1994-0002,FDA,FDA-2020-E-1994,Letter to U S Patent and Trademark Office,Other,Letter(s),2021-02-08T05:00:00Z,2021,2,2021-02-08T05:00:00Z,,2021-02-08T20:25:51Z,,0,0,0900006484a216e1
FDA-2020-E-1994-0001,FDA,FDA-2020-E-1994,Letter to U S Patent and Trademark Office,Other,Letter(s),2020-10-27T04:00:00Z,2020,10,2020-10-27T04:00:00Z,,2020-10-27T16:42:53Z,,0,0,0900006484937be4